Final analysis of a phase III RCT in 453 patients with resectable stage II-IIIA NSCLC: perioperative tislelizumab plus neoadjuvant chemotherapy improved OS vs placebo plus chemotherapy (HR 0.65; 36-month OS 79.3% vs 69.3%) and EFS (HR 0.58).
RCTn = 453
Wang et al. Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer: final analysis of the randomized RATIONALE-315 trial